PMID
Cmpds
Data
Article Title
Organization
40
The 1,2,4-Triazolo[4,3-a]pyrazin-3-one as a Versatile Scaffold for the Design of Potent Adenosine Human Receptor Antagonists. Structural Investigations to Target the A

Universita Degli Studi Di Firenze
24
N

Seoul National University
31
Design, Synthesis of Novel, Potent, Selective, Orally Bioavailable Adenosine A

Advinus Therapeutics
51
A

Advinus Therapeutics
33
Design and synthesis of novel, potent and selective hypoxanthine analogs as adenosine A

Advinus Therapeutics
18
Design, Synthesis, and Pharmacological Characterization of 2-(2-Furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine Derivatives: New Highly Potent A

Universita Degli Studi Di Firenze
24
Synthesis and evaluation of N-substituted 2-amino-4,5-diarylpyrimidines as selective adenosine A

Leiden University
49
Structure-anticonvulsant activity studies in the group of (E)-N-cinnamoyl aminoalkanols derivatives monosubstituted in phenyl ring with 4-Cl, 4-CH

Jagiellonian University Medical College
14
Discovery of 1,3-diethyl-7-methyl-8-(phenoxymethyl)-xanthine derivatives as novel adenosine A

North-West University
19
Quinazoline Carboxamides as Selective Antagonists of Adenosine 2A Receptor.

Dart Neuroscience
44
Biphenyl Pyridazinone Derivatives as Inhaled PDE4 Inhibitors: Structural Biology and Structure-Activity Relationships.

RhôNe-Poulenc Rorer
34
Structure-Based Scaffold Repurposing for G Protein-Coupled Receptors: Transformation of Adenosine Derivatives into 5HT

National Institute of Diabetes and Digestive and Kidney Diseases
39
Discovery of 7-(Prolinol-N-yl)-2-phenylamino-thiazolo[5,4-d]pyrimidines as Novel Non-Nucleoside Partial Agonists for the A2A Adenosine Receptor: Prediction from Molecular Modeling.

Julius-Maximilians-Universit£T W£Rzburg
38
Similarities and differences in affinity and binding modes of tricyclic pyrimido- and pyrazinoxanthines at human and rat adenosine receptors.

Jagiellonian University Medical College
5
5'-Substituted Amiloride Derivatives as Allosteric Modulators Binding in the Sodium Ion Pocket of the Adenosine A2A Receptor.

Leiden University
29
Exploring the 2- and 5-positions of the pyrazolo[4,3-d]pyrimidin-7-amino scaffold to target human A1 and A2A adenosine receptors.

Universita Degli Studi Di Firenze
37
Discovery of Potent and Highly Selective A2B Adenosine Receptor Antagonist Chemotypes.

Uppsala University
47
Design, physico-chemical properties and biological evaluation of some new N-[(phenoxy)alkyl]- and N-{2-[2-(phenoxy)ethoxy]ethyl}aminoalkanols as anticonvulsant agents.

Jagiellonian University Medical College
13
Discovery of Novel Adenosine Receptor Agonists That Exhibit Subtype Selectivity.

University of Warwick
24
Discovery of Molecular Therapeutics for Glaucoma: Challenges, Successes, and Promising Directions.

Georgia Institute of Technology
11
Carbamate substituted 2-amino-4,6-diphenylpyrimidines as adenosine receptor antagonists.

North-West University
47
Discovery of aminoquinazoline derivatives as human A(2A) adenosine receptor antagonists.

Merck Research Laboratories
33
Structural refinement of pyrazolo[4,3-d]pyrimidine derivatives to obtain highly potent and selective antagonists for the human A3 adenosine receptor.

Universita Degli Studi Di Firenze
33
5,7-Disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazines as pharmacological tools to explore the antagonist selectivity profiles toward adenosine receptors.

University of Trieste
19
1,3,7-Triethyl-substituted xanthines--possess nanomolar affinity for the adenosine A1 receptor.

North-West University
12
New Frontiers in Selective Human MAO-B Inhibitors.

Sapienza University of Rome
19
Use of molecular modeling aided design to dial out hERG liability in adenosine A(2A) receptor antagonists.

Merck Research Laboratories
15
One-pot reaction to obtain N,N'-disubstituted guanidines of pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidine scaffold as human A3 adenosine receptor antagonists.

University of Ferrara
12
A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D(1) and D(2) dopamine receptors.

University of Barcelona
45
Design, synthesis, and biological evaluation of novel 2-((2-(4-(substituted)phenylpiperazin-1-yl)ethyl)amino)-5'-N-ethylcarboxamidoadenosines as potent and selective agonists of the A2A adenosine receptor.

University of Ferrara
13
5'-C-Ethyl-tetrazolyl-N(6)-substituted adenosine and 2-chloro-adenosine derivatives as highly potent dual acting A1 adenosine receptor agonists and A3 adenosine receptor antagonists.

University of Camerino
32
A facile and novel synthesis of N(2)-, C(6)-substituted pyrazolo[3,4-d]pyrimidine-4 carboxylate derivatives as adenosine receptor antagonists.

National University of Singapore
17
Synthesis and SAR studies of analogues of 4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-N-thiazol-2-yl-benzamide (Lu AA41063) as adenosine A2A receptor ligands with improved aqueous solubility.

H. Lundbeck
18
Novel thiazole-thiophene conjugates as adenosine receptor antagonists: synthesis, biological evaluation and docking studies.

B. V. Patel Pharmaceutical Education and Research Development (Perd) Centre
28
Synthesis and pharmacological evaluation of dual acting ligands targeting the adenosine A2A and dopamine D2 receptors for the potential treatment of Parkinson's disease.

Monash University (Parkville Campus)
22
7-Amino-2-phenylpyrazolo[4,3-d]pyrimidine derivatives: structural investigations at the 5-position to target human A1 and A(2A) adenosine receptors. Molecular modeling and pharmacological studies.

University of Florence
64
Scaffold decoration at positions 5 and 8 of 1,2,4-triazolo[1,5-c]pyrimidines to explore the antagonist profiling on adenosine receptors: a preliminary structure-activity relationship study.

University of Trieste
13
Extended N(6) substitution of rigid C2-arylethynyl nucleosides for exploring the role of extracellular loops in ligand recognition at the A3 adenosine receptor.

National Institute of Diabetes and Digestive and Kidney Diseases
40
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).

Glaxosmithkline
1
DDD-028: a potent potential non-opioid, non-cannabinoid analgesic for neuropathic and inflammatory pain.

University of Missouri
20
1,2,4-triazolo[1,5-a]quinoxaline derivatives and their simplified analogues as adenosine A3 receptor antagonists. Synthesis, structure-affinity relationships and molecular modeling studies.

University of Florence
18
Further studies on pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as potent and selective human A1 adenosine receptor antagonists.

Universita Degli Studi Di Firenze
6
Discovery of a Potent and Selective DGAT1 Inhibitor with a Piperidinyl-oxy-cyclohexanecarboxylic Acid Moiety.

Merck Research Laboratories
5
Structure-Based Design of Reactive Nucleosides for Site-Specific Modification of the A2A Adenosine Receptor.

National Institute of Diabetes and Digestive and Kidney Diseases
20
8-Substituted 2-alkynyl-N(9)-propargyladenines as A2A adenosine receptor antagonists.

Yamasa
66
Adenosine A2A receptor as a drug discovery target.

Merck Research Laboratories
29
Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines.

Leiden University
46
Flavonoid derivatives as adenosine receptor antagonists: a comparison of the hypothetical receptor binding site based on a comparative molecular field analysis model.

National Institute of Diabetes
4
Structure-based approaches to ligands for G-protein-coupled adenosine and P2Y receptors, from small molecules to nanoconjugates.

National Institute of Diabetes and Digestive and Kidney Diseases
30
2-Arylpyrazolo[4,3-d]pyrimidin-7-amino derivatives as new potent and selective human A3 adenosine receptor antagonists. Molecular modeling studies and pharmacological evaluation.

University of Florence
18
Synthesis and structure-activity relationships of 2-hydrazinyladenosine derivatives as A(2A) adenosine receptor ligands.

University of Bonn
6
Metabolites of the pyrimidine amine preladenant as adenosine a2a receptor antagonists.

Dart Neuroscience
51
Synthesis of (E)-8-(3-chlorostyryl)caffeine analogues leading to 9-deazaxanthine derivatives as dual A(2A) antagonists/MAO-B inhibitors.

University of Parma
14
Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold.

University of Santiago De Compostela
16
Pyrazolo[1,5-c]quinazoline derivatives and their simplified analogues as adenosine receptor antagonists: synthesis, structure-affinity relationships and molecular modeling studies.

Universita' Di Firenze
19
Truncated Nucleosides as A(3) Adenosine Receptor Ligands: Combined 2-Arylethynyl and Bicyclohexane Substitutions.

TBA
8
Biophysical mapping of the adenosine A2A receptor.

Heptares Therapeutics
11
Synthesis and pharmacological evaluation of novel substituted 9-deazaxanthines as A2B receptor antagonists.

Universidade De A Coru£A
4
In silico directed chemical probing of the adenosine receptor family.

Universidade Do Minho
14
Synthesis and pharmacological evaluation of novel 1,3,8- and 1,3,7,8-substituted xanthines as adenosine receptor antagonists.

Universidade De Porto
33
Synthesis and pharmacological evaluation of novel 1- and 8-substituted-3-furfuryl xanthines as adenosine receptor antagonists.

Universidade De Santiago De Compostela
21
Synthesis of novel 1-alkyl-8-substituted-3-(3-methoxypropyl) xanthines as putative A(2B) receptor antagonists.

Universidade De A Coru£A
146
Design, synthesis, and structure-activity relationships of 1-,3-,8-, and 9-substituted-9-deazaxanthines at the human A2B adenosine receptor.

University of Bari Aldo Moro
61
Exploring the directionality of 5-substitutions in a new series of 5-alkylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine as a strategy to design novel human a(3) adenosine receptor antagonists.

University of Trieste
44
Medicinal chemistry of A3 adenosine receptor modulators: pharmacological activities and therapeutic implications.

University of Ferrara
25
Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity.

National Institute of Diabetes and Digestive and Kidney Diseases
6
Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data.

Leiden/Amsterdam Center For Drug Research
19
Orally active adenosine A(1) receptor agonists with antinociceptive effects in mice.

University of North Carolina at Chapel Hill
13
Design and characterization of optimized adenosine A2A/A1 receptor antagonists for the treatment of Parkinson's disease.

Janssen Research and Development
38
Synthesis and biological activity of tricyclic cycloalkylimidazo-, pyrimido- and diazepinopurinediones.

Jagiellonian University Medical College
33
Structure-activity relationships and molecular modeling of 1,2,4-triazoles as adenosine receptor antagonists.

TBA
32
Water-soluble pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists.

University of Ferrara
27
A prospective cross-screening study on G-protein-coupled receptors: lessons learned in virtual compound library design.

Radboud University Nijmegen Medical Centre
10
Optimization of adenosine 5'-carboxamide derivatives as adenosine receptor agonists using structure-based ligand design and fragment screening.

National Institute of Diabetes and Digestive and Kidney Diseases
30
Structure-guided design of A(3) adenosine receptor-selective nucleosides: combination of 2-arylethynyl and bicyclo[3.1.0]hexane substitutions.

National Institute of Diabetes and Digestive and Kidney Diseases
16
New chromene scaffolds for adenosine A(2A) receptors: synthesis, pharmacology and structure-activity relationships.

Universidade Do Minho
16
Synthesis and pharmacological evaluation of dual acting antioxidant A(2A) adenosine receptor agonists.

Monash University
7
Development of Polar Adenosine A2A Receptor Agonists for Inflammatory Bowel Disease: Synergism with A2B Antagonists.

TBA
17
3-aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one: a novel template for the design of highly selective A2B adenosine receptor antagonists.

University of Pisa
16
Identification of novel adenosine A(2A) receptor antagonists by virtual screening.

Heptares Therapeutics
12
Discovery of 1,2,4-triazine derivatives as adenosine A(2A) antagonists using structure based drug design.

Heptares Therapeutics
12
Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c

Cephalon
23
Truncated (N)-Methanocarba Nucleosides as A(1) Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element.

TBA
5
Discovery of New Human A(2A) Adenosine Receptor Agonists: Design, Synthesis, and Binding Mode of Truncated 2-Hexynyl-4'-thioadenosine.

Ewha Womans University
23
Discovery of phosphoric acid mono-{2-[(E/Z)-4-(3,3-dimethyl-butyrylamino)-3,5-difluoro-benzoylimino]-thiazol-3-ylmethyl} ester (Lu AA47070): a phosphonooxymethylene prodrug of a potent and selective hA(2A) receptor antagonist.

H. Lundbeck
39
Discovery of {1-[4-(2-{hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl}-1H-benzimidazol-1-yl)piperidin-1-yl]cyclooctyl}methanol, systemically potent novel non-peptide agonist of nociceptin/orphanin FQ receptor as analgesic for the treatment of neuropathic pain: design, synthesis, and structure-activity rela

Pfizer
49
Discovery of a novel 5-HT(3) antagonist/5-HT(1A) agonist 3-amino-5,6,7,8-tetrahydro-2-{4-[4-(quinolin-2-yl)piperazin-1-yl]butyl}quinazolin-4(3H)-one (TZB-30878) as an orally bioavailable agent for irritable bowel syndrome.

ASKA Pharmaceutical Co
34
Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential.

H. Lundbeck
38
4-Substituted-7-N-alkyl-N-acetyl 2-aminobenzothiazole amides: drug-like and non-xanthine based A2B adenosine receptor antagonists.

Roche Research Center
28
Novel N2-substituted pyrazolo[3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation.

University of Pisa
12
Novel 8-(furan-2-yl)-3-substituted thiazolo [5,4-e][1,2,4] triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A(2A) receptor antagonists.

University of Delhi
33
2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists.

University of Bonn
43
1-alkyl-8-(piperazine-1-sulfonyl)phenylxanthines: development and characterization of adenosine A2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity.

Institute
50
8-Bromo-9-alkyl adenine derivatives as tools for developing new adenosine A2A and A2B receptors ligands.

University of Camerino
45
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists.

Leiden/Amsterdam Center For Drug Research
11
Synthesis of eudistomin D analogues and its effects on adenosine receptors.

Hokkaido University
24
Design of (N)-methanocarba adenosine 5'-uronamides as species-independent A3 receptor-selective agonists.

National Institute of Diabetes and Digestive and Kidney Diseases
67
Antagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines.

Vernalis (R&D)
39
Antagonists of the human adenosine A2A receptor. Part 2: Design and synthesis of 4-arylthieno[3,2-d]pyrimidine derivatives.

Vernalis (R&D)
28
Antagonists of the human adenosine A2A receptor. Part 1: Discovery and synthesis of thieno[3,2-d]pyrimidine-4-methanone derivatives.

Vernalis (R&D)
45
Discovery of a novel A2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases.

Cv Therapeutics
76
Probing distal regions of the A2B adenosine receptor by quantitative structure-activity relationship modeling of known and novel agonists.

National Institute of Diabetes and Digestive and Kidney Diseases
22
1,3-Dipropyl-8-(1-phenylacetamide-1H-pyrazol-3-yl)-xanthine derivatives as highly potent and selective human A(2B) adenosine receptor antagonists.

University of Ferrara
34
A new generation of adenosine receptor antagonists: from di- to trisubstituted aminopyrimidines.

Leiden/Amsterdam Center For Drug Research
77
1-, 3- and 8-substituted-9-deazaxanthines as potent and selective antagonists at the human A2B adenosine receptor.

University of Bari Aldo Moro
2
A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.

Abbott Laboratories
22
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-N,N-dialkyluronamides as human A3 adenosine receptor antagonists.

Ewha Womans University
19
2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liability.

Neurocrine Biosciences
11
Inhaled adenosine A(2A) receptor agonists for the treatment of chronic obstructive pulmonary disease.

Pfizer
38
Multi-target-directed ligands to combat neurodegenerative diseases.

University of Bologna
32
5'-Carbamoyl derivatives of 2'-C-methyl-purine nucleosides as selective A1 adenosine receptor agonists: affinity, efficacy, and selectivity for A1 receptor from different species.

University of Camerino
12
Structure-activity relationships of adenosines with heterocyclic N6-substituents.

Monash University (Parkville Campus)
33
5-amino-2-phenyl[1,2,3]triazolo[1,2-a][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists.

University of Pisa
21
N(6)-[(hetero)aryl/(cyclo)alkyl-carbamoyl-methoxy-phenyl]-(2-chloro)-5'-N-ethylcarboxamido-adenosines: the first example of adenosine-related structures with potent agonist activity at the human A(2B) adenosine receptor.

University of Ferrara
77
Novel bicyclic piperazine derivatives of triazolotriazine and triazolopyrimidines as highly potent and selective adenosine A2A receptor antagonists.

Biogen Idec
36
Structure-activity relationships of 2,N(6),5'-substituted adenosine derivatives with potent activity at the A2B adenosine receptor.

National Institute of Diabetes and Digestive and Kidney Diseases
36
N6-methoxy-2-alkynyladenosine derivatives as highly potent and selective ligands at the human A3 adenosine receptor.

University of Camerino
19
Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazino]- 9H-purin-9-yl]-N-ethyl-beta-D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists.

University of Ferrara
8
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-alpha]pyridines as potent inhibitors of human eosinophil phosphodiesterase.

Pfizer
4
Structure-activity relationship study of prion inhibition by 2-aminopyridine-3,5-dicarbonitrile-based compounds: parallel synthesis, bioactivity, and in vitro pharmacokinetics.

University of California San Francisco
31
N6-ethyl-2-alkynyl NECAs, selective human A3 adenosine receptor agonists.

University of Virginia
16
Synthesis and biological studies of a new series of 5-heteroarylcarbamoylaminopyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidines as human A3 adenosine receptor antagonists. Influence of the heteroaryl substituent on binding affinity and molecular modeling investigations.

University of Trieste
27
2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching.

University of Naples Federico II
47
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.

University of Urbino
6
Development of spin-labeled probes for adenosine receptors.

University of Bonn
20
A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor.

Leiden/Amsterdam Center For Drug Research
55
Novel diamino derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

Biogen Idec
22
Synthesis, biological evaluation, and molecular modeling of ribose-modified adenosine analogues as adenosine receptor agonists.

University of Camerino
22
Synthesis and biological evaluation of novel N6-[4-(substituted)sulfonamidophenylcarbamoyl]adenosine-5'-uronamides as A3 adenosine receptor agonists.

University of Ferrara
23
2-Pyrazolyl-N(6)-substituted adenosine derivatives as high affinity and selective adenosine A(3) receptor agonists.

Cv Therapeutics
8
Synthesis and biological activity of new potential agonists for the human adenosine A2A receptor.

Iiqab (Csic)
7
A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential.

Novartis Institutes For Biomedical Research
2
Design and synthesis of 3'-ureidoadenosine-5'-uronamides: effects of the 3'-ureido group on binding to the A3 adenosine receptor.

Ewha Womans University
5
Novel amino acid derived natural products from the ascidian Atriolum robustum: identification and pharmacological characterization of a unique adenosine derivative.

University of Bonn
69
Design, synthesis, and biological evaluation of new 8-heterocyclic xanthine derivatives as highly potent and selective human A2B adenosine receptor antagonists.

University of Ferrara
6
New, non-adenosine, high-potency agonists for the human adenosine A2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine.

University of Leiden
24
1,2,4-triazolo[4,3-a]quinoxalin-1-one moiety as an attractive scaffold to develop new potent and selective human A3 adenosine receptor antagonists: synthesis, pharmacological, and ligand-receptor modeling studies.

Universita Degli Studi Di Firenze
4
N6-cyclopentyl-2-(3-phenylaminocarbonyltriazene-1-yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor.

Leiden University
25
Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A2A and A3 adenosine receptors antagonists.

University of Ferrara
7
Modeling the adenosine receptors: comparison of the binding domains of A2A agonists and antagonists.

Niddk
8
Ribose-modified nucleosides as ligands for adenosine receptors: synthesis, conformational analysis, and biological evaluation of 1'-C-methyl adenosine analogues.

University of Camerino
35
Synthesis, molecular modeling studies, and pharmacological activity of selective A(1) receptor antagonists.

University of Genoa
3
2,5'-Disubstituted adenosine derivatives: evaluation of selectivity and efficacy for the adenosine A(1), A(2A), and A(3) receptor.

Leiden/Amsterdam Center For Drug Research
25
Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A(2A)- and A(3)-adenosine receptor antagonists.

University of Bonn
2
N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands.

University of Camerino
41
Thiazole and thiadiazole analogues as a novel class of adenosine receptor antagonists.

Vrije Universiteit
86
Design, synthesis, and evaluation of novel A2A adenosine receptor agonists.

University of Virginia
25
3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.

University of Pisa
15
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.

National Institute of Diabetes and Digestive and Kidney Diseases
39
Nucleosides and nucleotides. 200. Reinvestigation of 5'-N-ethylcarboxamidoadenosine derivatives: structure-activity relationships for P(3) purinoceptor-like proteins.

Hokkaido University
20
N-cycloalkyl derivatives of adenosine and 1-deazaadenosine as agonists and partial agonists of the A(1) adenosine receptor.

University of Camerino
34
A novel class of highly potent and selective A1 adenosine antagonists: structure-affinity profile of a series of 1,8-naphthyridine derivatives.

University of Pisa
13
Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists.

National Institute of Diabetes
15
Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.

Neogenesis
9
N6,5'-Disubstituted adenosine derivatives as partial agonists for the human adenosine A3 receptor.

Leiden/Amsterdam Center For Drug Research
4
5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.

Leiden University
16
Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.

National Institute of Diabetes
35
Synthesis and biological activity of a new series of N6-arylcarbamoyl, 2-(Ar)alkynyl-N6-arylcarbamoyl, and N6-carboxamido derivatives of adenosine-5'-N-ethyluronamide as A1 and A3 adenosine receptor agonists.

University of Ferrara
2
Nucleosides and nucleotides. 177. 9-(6,7-dideoxy-beta-D-allo-hept-5- ynofuranosyl)adenine: a selective and potent ligand for P3 purinoceptor-like protein.

Hokkaido University
18
2'-C-Methyl analogues of selective adenosine receptor agonists: synthesis and binding studies.

University of Camerino
10
5'-substituted adenosine analogs as new high-affinity partial agonists for the adenosine A1 receptor.

Leiden/Amsterdam Center For Drug Research
19
N6-cyclopentyl-3'-substituted-xylofuranosyladenosines: a new class of non-xanthine adenosine A1 receptor antagonists.

University of Ghent
11
Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors.

Niddk
23
Novel N6-(substituted-phenylcarbamoyl)adenosine-5'-uronamides as potent agonists for A3 adenosine receptors.

University of Ferrara
32
6-phenyl-1,4-dihydropyridine derivatives as potent and selective A3 adenosine receptor antagonists.

National Institute of Diabetes
14
2-alkenyl and 2-alkyl derivatives of adenosine and adenosine-5'-N-ethyluronamide: different affinity and selectivity of E- and Z-diastereomers at A2A adenosine receptors.

University of Camerino
28
Interaction of 1,4-dihydropyridine and pyridine derivatives with adenosine receptors: selectivity for A3 receptors.

National Institute of Diabetes
36
2-Aralkynyl and 2-heteroalkynyl derivatives of adenosine-5'-N-ethyluronamide as selective A2a adenosine receptor agonists.

University of Camerino
43
Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors.

National Institute of Diabetes
15
Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.

Leiden University
14
2-[N'-(3-arylallylidene)hydrazino]adenosines showing A2a adenosine agonist properties and vasodilation activity.

University of Milan
37
Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A3 adenosine receptors.

National Institute of Diabetes
16
Selective ligands for rat A3 adenosine receptors: structure-activity relationships of 1,3-dialkylxanthine 7-riboside derivatives.

National Institute of Diabetes
16
2-Substitution of N6-benzyladenosine-5'-uronamides enhances selectivity for A3 adenosine receptors.

National Institute of Diabetes
2
Synthesis and biological evaluation of N4-substituted imidazo- and v-triazolo[4,5-d]pyridazine nucleosides.

University of Rhode Island
20
Nucleosides and nucleotides. 112. 2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry of selective A2 adenosine receptor agonists with potent antihypertensive activity.

Hokkaido University
9
Activity of N6-substituted 2-chloroadenosines at A1 and A2 adenosine receptors.

University of South Florida
25
1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors.

TBA
9
Adenosine receptors: targets for future drugs.

TBA
4
Design, synthesis and binding affinity of 3'-fluoro analogues of Cl-IB-MECA as adenosine A3 receptor ligands.

Seoul National University
6
7-Nitrobenzofurazan (NBD) derivatives of 5'-N-ethylcarboxamidoadenosine (NECA) as new fluorescent probes for human A(3) adenosine receptors.

University of Pisa
5
Introduction of alkynyl chains on C-8 of adenosine led to very selective antagonists of the A(3) adenosine receptor.

University of Camerino
16
Ring-Constrained (N)-methanocarba nucleosides as adenosine receptor agonists: independent 5'-uronamide and 2'-deoxy modifications.

Niddk
19
The discovery and synthesis of highly potent, A2a receptor agonists.

Glaxowellcome Medicines Research Centre
11
2-Nitro analogues of adenosine and 1-deazaadenosine: synthesis and binding studies at the adenosine A1, A2A and A3 receptor subtypes.

University of Amsterdam
12
Diimidazo[1,2-c:4',5'-e]pyrimidines: N6-N1 conformationally restricted adenosines.

Griffith University
16
New base-altered adenosine analogues: Synthesis and affinity at adenosine A1 and A2A receptors

TBA
39
Novel 1,3-dipropyl-8-(3-benzimidazol-2-yl-methoxy-1-methylpyrazol-5-yl)xanthines as potent and selective A2B adenosine receptor antagonists.

University of Ferrara
33
Evaluation of molecular modeling of agonist binding in light of the crystallographic structure of an agonist-bound A2A adenosine receptor.

National Institute of Diabetes and Digestive and Kidney Diseases
17
Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A2A and A3 adenosine receptor ligands.

Ewha Womans University
33
Pyrrolo- and pyrazolo-[3,4-e][1,2,4]triazolo[1,5-c]pyrimidines as adenosine receptor antagonists.

University of Ferrara
37
Synthesis and Biological Evaluation of a New Series of 1,2,4-Triazolo[1,5-a]-1,3,5-triazines as Human A(2A) Adenosine Receptor Antagonists with Improved Water Solubility.

Universita Di Trieste
78
Highly potent, selective, and orally active phosphodiesterase 10A inhibitors.

Pfizer
25
Does the combination of optimal substitutions at the C²-, N¿?¿- and N¿?¿-positions of the pyrazolo-triazolo-pyrimidine scaffold guarantee selective modulation of the human A3 adenosine receptors?

National University of Singapore
33
New 2-heterocyclyl-imidazo[2,1-i]purin-5-one derivatives as potent and selective human A3 adenosine receptor antagonists.

University of Ferrara
12
Progress in structure based drug design for G protein-coupled receptors.

Heptares Therapeutics
8
Synthesis, structure-affinity relationships, and molecular modeling studies of novel pyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.

Universita' Di Firenze
13
Molecular probes for the A2A adenosine receptor based on a pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine scaffold.

National Institute of Diabetes and Digestive and Kidney Diseases
22
Discovery of benzothiazole-based adenosine A2B receptor antagonists with improved A2A selectivity.

Roche Research Center
29
Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.

Merck Research Laboratories
23
Discovery of LAS101057: A Potent, Selective, and Orally Efficacious A
2B Adenosine Receptor Antagonist

TBA
72
Pyrimidine derivatives as potent and selective A3 adenosine receptor antagonists.

University of Santiago De Compostela
34
Discovery of novel quinolinone adenosine A2B antagonists.

Ligand Pharmaceuticals
1
In vivo characterization of a dual adenosine A2A/A1 receptor antagonist in animal models of Parkinson's disease.

Johnson & Johnson Pharmaceutical Research and Development
12
Molecular modeling study on potent and selective adenosine A(3) receptor agonists.

University of Camerino
30
Pyrazolo[1',5':1,6]pyrimido[4,5-d]pyridazin-4(3H)-ones as selective human A(1) adenosine receptor ligands.

Dipartimento Di Scienze Farmaceutiche
37
Discovery of 2-aminoimidazopyridine adenosine A(2A) receptor antagonists.

Ligand Pharmaceuticals
13
Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists.

Niddk
21
Identification and optimization of substituted 5-aminopyrazoles as potent and selective adenosine A1 receptor antagonists.

Bayer Schering Pharma
2
Design, synthesis, and binding of homologated truncated 4'-thioadenosine derivatives at the human A3 adenosine receptors.

Ewha Womans University
1
Spiroindolones, a potent compound class for the treatment of malaria.

Swiss Tropical and Public Health Institute
28
Hit-to-lead optimization of a series of carboxamides of ethyl 2-amino-4-phenylthiazole-5-carboxylates as novel adenosine A2A receptor antagonists.

H. Lundbeck
21
A new group of oxime carbamates as reversible inhibitors of fatty acid amide hydrolase.

Università
31
Insights into binding modes of adenosine A(2B) antagonists with ligand-based and receptor-based methods.

East China University of Science and Technology
12
Structure-based discovery of A2A adenosine receptor ligands.

University of California
23
Synthesis and evaluation of new N6-substituted adenosine-5'-N-methylcarboxamides as A3 adenosine receptor agonists.

Monash University
34
Methylene amine substituted arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.

Johnson & Johnson Pharmaceutical Research and Development
36
Optimization of arylindenopyrimidines as potent adenosine A(2A)/A(1) antagonists.

Johnson & Johnson Pharmaceutical Research and Development
9
Synthesis and theoretical studies on energetics of novel N- and O- perfluoroalkyl triazole tagged thienopyrimidines--their potential as adenosine receptor ligands.

Institute of Chemical Technology
15
SAR of a series of inhaled A(2A) agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data.

Pfizer
32
The significance of 2-furyl ring substitution with a 2-(para-substituted) aryl group in a new series of pyrazolo-triazolo-pyrimidines as potent and highly selective hA(3) adenosine receptors antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition.

National University of Singapore
21
Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: A preliminary inspection of ligand-receptor recognition process.

National University of Singapore
9
Discovery of potent and selective bicyclic A(2B) adenosine receptor antagonists via bioisosteric amide replacement.

RhôNe-Poulenc Rorer
29
Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A(2B) adenosine receptor antagonists.

RhôNe-Poulenc Rorer
42
Discovery and optimization of potent and selective functional antagonists of the human adenosine A2B receptor.

Vernalis (R&D)
20
2-Dialkynyl derivatives of (N)-methanocarba nucleosides: 'Clickable' A(3) adenosine receptor-selective agonists.

Niddk
28
Synthesis and evaluation of two series of 4'-aza-carbocyclic nucleosides as adenosine A2A receptor agonists.

Novartis Institutes For Biomedical Research
8
Synthesis of theophylline derivatives and study of their activity as antagonists at adenosine receptors.

Universidad De M£Laga
56
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists.

The Scripps Research Institute
27
Design and synthesis of N(6)-substituted-4'-thioadenosine-5'-uronamides as potent and selective human A(3) adenosine receptor agonists.

Ewha Womans University
20
Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists.

Tsukuba Research Institute
12
Nucleoside-5'-monophosphates as prodrugs of adenosine A2A receptor agonists activated by ecto-5'-nucleotidase.

University of Bonn
11
2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition.

University of Florence
27
Functionalized congeners of A3 adenosine receptor-selective nucleosides containing a bicyclo[3.1.0]hexane ring system.

National Institute of Diabetes and Digestive and Kidney Diseases
11
Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5'-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A3 receptor.

University of Camerino
4
Design, synthesis and biological evaluation of a bivalent micro opiate and adenosine A1 receptor antagonist.

Aix-Marseille Universit£
186
Combining selectivity and affinity predictions using an integrated Support Vector Machine (SVM) approach: An alternative tool to discriminate between the human adenosine A(2A) and A(3) receptor pyrazolo-triazolo-pyrimidine antagonists binding sites.

University of Padova
10
Synthesis of hybrid analogues of caffeine and eudistomin D and its affinity for adenosine receptors.

Hokkaido University
13
Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists.

Ewha Womans University
28
Antagonists of the human A(2A) receptor. Part 5: Highly bio-available pyrimidine-4-carboxamides.

Vernalis (R+D)
18
Adenosine A
2A antagonists with potent anti-cataleptic activity

TBA
4
Pyrazolo[3,4-
d]pyrimidines: C4, C6 substitution leads to adenosine A
1 receptor selectivity

TBA
6
Pyrazolo[3,4-
d]pyrimidines; adenosine receptor selectivity

TBA
16
Synthesis of new pyrazolo[4,3-e]1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine displaying potent and selective activity as A
2a adenosine receptor antagonists.

TBA
20
1,3-dialkyl-8-N-substituted benzyloxycarbonylamino-9-deazaxanthines as potent adenosine receptor ligands: Design, synthesis, structure-affinity and structure-selectivity relationships.

Universidade De Santiago De Compostela
19
N6-Cycloalkyl- and N6-bicycloalkyl-C5'(C2')-modified adenosine derivatives as high-affinity and selective agonists at the human A1 adenosine receptor with antinociceptive effects in mice.

University of Camerino
29
Pyrido[2,3-e]-1,2,4-triazolo[4,3-a]pyrazin-1-one as a new scaffold to develop potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

Universita Di Firenze
31
Synthesis, biological assays and QSAR studies of N-(9-benzyl-2-phenyl-8-azapurin-6-yl)-amides as ligands for A1 adenosine receptors.

Università
32
Synthesis and SAR studies of trisubstituted purinones as potent and selective adenosine A2A receptor antagonists.

Pharmacopeia
37
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy.

Neurocrine Biosciences
30
Potent and selective adenosine A2A receptor antagonists: 1,2,4-Triazolo[1,5-c]pyrimidines.

Schering-Plough Research Institute
19
Synthesis of 2-amino-5-benzoyl-4-(2-furyl)thiazoles as adenosine A(2A) receptor antagonists.

Pharmacopeia
16
Synthesis of a series of 8-(substituted-phenyl)xanthines and a study on the effects of substitution pattern of phenyl substituents on affinity for adenosine A(1) and A(2A) receptors.

University Institute of Pharmaceutical Sciences
34
Structure-activity relationship studies of a new series of imidazo[2,1-f]purinones as potent and selective A(3) adenosine receptor antagonists.

Università
25
Novel potent and highly selective human A(3) adenosine receptor antagonists belonging to the 4-amido-2-arylpyrazolo[3,4-c]quinoline series: molecular docking analysis and pharmacological studies.

Università
33
1,3-Dialkyl-8-(hetero)aryl-9-OH-9-deazaxanthines as potent A2B adenosine receptor antagonists: design, synthesis, structure-affinity and structure-selectivity relationships.

Università
31
2,6-Diaryl-4-acylaminopyrimidines as potent and selective adenosine A(2A) antagonists with improved solubility and metabolic stability.

Neurocrine Biosciences
14
Structure-activity relationships of truncated D- and l-4'-thioadenosine derivatives as species-independent A3 adenosine receptor antagonists.

Ewha Womans University
18
Selective A(3) adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system.

National Institute of Diabetes and Digestive and Kidney Diseases
12
Dual inhibition of monoamine oxidase B and antagonism of the adenosine A(2A) receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues.

North-West University
18
Biaryl and heteroaryl derivatives of SCH 58261 as potent and selective adenosine A2A receptor antagonists.

Schering-Plough Research Institute
26
Design, synthesis, and evaluation of fused heterocyclic analogs of SCH 58261 as adenosine A2A receptor antagonists.

Schering-Plough Research Institute
23
Synthesis, ligand-receptor modeling studies and pharmacological evaluation of novel 4-modified-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-one derivatives as potent and selective human A3 adenosine receptor antagonists.

Universita' Di Firenze
5
N6-1,3-diphenylurea derivatives of 2-phenyl-9-benzyladenines and 8-azaadenines: synthesis and biological evaluation as allosteric modulators of A2A adenosine receptors.

Università
4
Synthesis and adenosine receptor binding studies of some novel triazolothienopyrimidines.

University College of Pharmaceutical Sciences
4
Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A(1) adenosine receptors.

University of Bonn
1
Discovery of the First Efficacious Adenosine 2A Receptor Negative Allosteric Modulators for High Adenosine Cancer Immunotherapies.

University of Geneva
24
Progress in the study of anti-Alzheimer's disease activity of pyrimidine-containing bioactive molecules.

Zhengzhou University
8
Synthesis and biological evaluation of sugar-modified truncated carbanucleosides as A2A and A3 adenosine receptor ligands to explore conformational effect to the receptors.

Seoul National University
3
Bioactive pyridoacridine alkaloids from the micronesian sponge Oceanapia sp.

Institut FüR Biowissenschaften
33
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonists.

Neurocrine Biosciences
38
Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines.

Cv Therapeutics
46
Quinazolines annelated at the N(3)-C(4) bond: Synthesis and biological activity.

Ural Federal University
9
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacy.

Neurocrine Biosciences
33
Structural Modification and Biological Evaluation of 2,8-Disubstituted Adenine and Its Nucleosides as A2A Adenosine Receptor Antagonists: Exploring the Roles of Ribose at Adenosine Receptors.

Seoul National University
31
Phenylethyl-substituted pyrimido[2,1-f]purinediones and related compounds: structure-activity relationships as adenosine A(1) and A(2A) receptor ligands.

Jagiellonian University Medical College
9
Dual acting antioxidant A1 adenosine receptor agonists.

Monash University (Parkville Campus)
33
New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

Università
14
Discovery of a new nucleoside template for human A3 adenosine receptor ligands: D-4'-thioadenosine derivatives without 4'-hydroxymethyl group as highly potent and selective antagonists.

Ewha Womans University
6
Novel Adenosine Receptor Antagonists for Treating Cancer and Immune-Related Disorders.

Smith, Gambrell & Russell
10
Novel ergopeptides as dual ligands for adenosine and dopamine receptors.

Institut D'Investigacions BiomèDiques August Pi I
32
3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists.

Glaxosmithkline
22
N9-benzyl-substituted 1,3-dimethyl- and 1,3-dipropyl-pyrimido[2,1-f]purinediones: synthesis and structure-activity relationships at adenosine A1 and A2A receptors.

Jagiellonian University
22
Structure-Activity Relationship of Truncated 2,8-Disubstituted-Adenosine Derivatives as Dual A

Seoul National University
10
Discovery and characterization of 4'-(2-furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist.

Almirall
30
The Hitchhiker's Guide to Deep Learning Driven Generative Chemistry.

Insilico Medicine Hong Kong
2
Neuroprotective principles from Gastrodia elata.

National Research Institute of Chinese Medicine
12
2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists.

Leiden/Amsterdam Center For Drug Research
70
Exploring the Effect of Halogenation in a Series of Potent and Selective A

University of Santiago de Compostela
19
Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines.

Schering-Plough Research Institute
28
3H-[1,2,4]-Triazolo[5,1-i]purin-5-amine derivatives as adenosine A2A antagonists.

Schering-Plough Research Institute
21
Recent advances in small molecule based cancer immunotherapy.

Southern Medical University
23
2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists.

Ghent University
21
Tricyclic imidazoline derivatives as potent and selective adenosine A1 receptor antagonists.

Biogen Idec
21
Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists.

Biogen Idec
37
N6-Cycloalkyl-2-substituted adenosine derivatives as selective, high affinity adenosine A1 receptor agonists.

Cv Therapeutics
25
Expanding the repertoire of methanocarba nucleosides from purinergic signaling to diverse targets.

National Institute of Diabetes & Digestive & Kidney Diseases
17
Identification of non-furan containing A2A antagonists using database mining and molecular similarity approaches.

Vernalis (R&D)
15
A new synthesis of sulfonamides by aminolysis of p-nitrophenylsulfonates yielding potent and selective adenosine A2B receptor antagonists.

University of Bonn
60
Pharmacophore based receptor modeling: the case of adenosine A3 receptor antagonists. An approach to the optimization of protein models.

Università
24
4-amido-2-aryl-1,2,4-triazolo[4,3-a]quinoxalin-1-ones as new potent and selective human A3 adenosine receptor antagonists. synthesis, pharmacological evaluation, and ligand-receptor modeling studies.

Università
60
Novel 1,3-disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) xanthines: high affinity and selective A2B adenosine receptor antagonists.

Cv Therapeutics
5
Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor.

Leiden University
16
2,6-disubstituted and 2,6,8-trisubstituted purines as adenosine receptor antagonists.

Leiden/Amsterdam Center For Drug Research
45
Dual-acting antitumor agents targeting the A

Shanghaitech University
32
A

National Institute of Diabetes and Digestive and Kidney Disease
2
Synthesis, in vitro and in vivo evaluation of [O-methyl-11C] 2-{4-[4-(3-methoxyphenyl)piperazin-1-yl]-butyl}-4-methyl-2H-[1,2,4]-triazine-3,5-dione: a novel agonist 5-HT1A receptor PET ligand.

Columbia University College of Physicians and Surgeons
39
Structure-activity relationships of 2-chloro-N6-substituted-4'-thioadenosine-5'-uronamides as highly potent and selective agonists at the human A3 adenosine receptor.

Ewha Womans University
2
Synthesis and in vivo validation of [O-methyl-11C]2-{4-[4-(7-methoxynaphthalen-1-yl)piperazin- 1-yl]butyl}-4-methyl-2H-[1,2,4]triazine-3,5-dione: a novel 5-HT1A receptor agonist positron emission tomography ligand.

Columbia University College of Physicians and Surgeons
28
Discovery of Novel Benzo[4,5]imidazo[1,2-

Sun Yat-Sen University
3
Semi-rational design of (north)-methanocarba nucleosides as dual acting A(1) and A(3) adenosine receptor agonists: novel prototypes for cardioprotection.

National Institute of Diabetes and Digestive and Kidney Diseases
31
1,2,4-Triazolo[1,5-a]quinoxaline as a versatile tool for the design of selective human A3 adenosine receptor antagonists: synthesis, biological evaluation, and molecular modeling studies of 2-(hetero)aryl- and 2-carboxy-substituted derivatives.

Università
3
Conversion of A3 adenosine receptor agonists into selective antagonists by modification of the 5'-ribofuran-uronamide moiety.

National Institute of Diabetes and Digestive and Kidney Diseases
41
Synthesis and 3D QSAR of new pyrazolo[3,4-b]pyridines: potent and selective inhibitors of A1 adenosine receptors.

Università
34
Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists.

Cv Therapeutics
46
Synthesis of [1,2,4]triazolo[1,5-a]pyrazines as adenosine A2A receptor antagonists.

Biogen Idec
40
1,8-Naphthyridin-4-one derivatives as new ligands of A2A adenosine receptors.

Dipartimento Di Scienze Farmaceutiche
11
New 2-arylpyrazolo[4,3-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists.

Università
23
"Reversine" and its 2-substituted adenine derivatives as potent and selective A3 adenosine receptor antagonists.

National Institute of Diabetes and Digestive and Kidney Diseases
16
New pyrrolo[2,1-f]purine-2,4-dione and imidazo[2,1-f]purine-2,4-dione derivatives as potent and selective human A3 adenosine receptor antagonists.

Università
1
GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A

University of Southern California
29
Surface Plasmon Resonance Screening to Identify Active and Selective Adenosine Receptor Binding Fragments.

University of Dundee
40
2-(2-Furanyl)-7-phenyl[1,2,4]triazolo[1,5-c]pyrimidin-5-amine analogs: highly potent, orally active, adenosine A2A antagonists. Part 1.

Schering-Plough Research Institute
27
Discovery of small-molecule compounds and natural products against Parkinson's disease: Pathological mechanism and structural modification.

Zhejiang University
143
Adenosine receptor antagonists: Recent advances and therapeutic perspective.

Isf College of Pharmacy
21
Examining the Role of the Linker in Bitopic

Monash University
21
6-(2-Furanyl)-9H-purin-2-amine derivatives as A2A adenosine antagonists.

Schering-Plough Research Institute
28
(N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists.

National Institute of Diabetes and Digestive and Kidney Diseases
38
High ligand efficiency quinazoline compounds as novel A

Univ. Lille
33
The discovery of a selective, high affinity A(2B) adenosine receptor antagonist for the potential treatment of asthma.

Cv Therapeutics
24
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.

Biogen Idec
32
Discovery and Structure-Activity Relationship Studies of Novel Adenosine A

University of Bern
31
2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists.

Leiden/Amsterdam Center For Drug Research
58
Design, Synthesis, and Bioevaluation of 2-Aminopteridin-7(8

Fudan University
10
Discovery of Pyridone-Substituted Triazolopyrimidine Dual A

Fudan University
88
Optimization of 2-Amino-4,6-diarylpyrimidine-5-carbonitriles as Potent and Selective A

Universidade De Santiago De Compostela
26
Development and Application of Subtype-Selective Fluorescent Antagonists for the Study of the Human Adenosine A

Monash University
18
Selective A

National Institute of Diabetes and Digestive and Kidney Diseases
15
Triamino derivatives of triazolotriazine and triazolopyrimidine as adenosine A2a receptor antagonists.

Biogen Idec
25
Studies on adenosine A2a receptor antagonists: comparison of three core heterocycles.

Biogen Idec
43
Piperazine derivatives of [1,2,4]triazolo[1,5-a][1,3,5]triazine as potent and selective adenosine A2a receptor antagonists.

Biogen Idec
7
Crystal Structure and Subsequent Ligand Design of a Nonriboside Partial Agonist Bound to the Adenosine A

Leiden University
18
Development of Covalent, Clickable Probes for Adenosine A

Monash University
22
Exploring Non-orthosteric Interactions with a Series of Potent and Selective A

Universidade De Santiago De Compostela
45
Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma.

Otsuka Pharmaceutical Factory
16
Adenosine A

Heinrich Heine University Duesseldorf
43
Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A

Shanghaitech University
4
Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A

Ewha Womans University
53
Study on affinity profile toward native human and bovine adenosine receptors of a series of 1,8-naphthyridine derivatives.

Università
42
Comparison of inhibitory activity of isomeric triazolopyridine derivatives towards adenosine receptor subtypes or do similar structures reveal similar bioactivities?

F. Hoffmann-La Roche
29
Discovery of Potent, Selective, and Brain-Penetrant Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitors that Modulate Brain Inflammation

Biogen
10
Adenosine Receptor Antagonists as Potential Cancer Therapy.

Therachem Research Medilab
9
Facile synthesis of fused 1,2,4-triazolo[1,5-c]pyrimidine derivatives as human adenosine A3 receptor ligands.

Otsuka Pharmaceutical Factory
11
2-(N-acyl) and 2-N-acyl-N(6)-substituted analogues of adenosine and their affinity at the human adenosine receptors.

Inotek Pharmaceuticals
20
Preparation, properties, reactions, and adenosine receptor affinities of sulfophenylxanthine nitrophenyl esters: toward the development of sulfonic acid prodrugs with peroral bioavailability.

University of Bonn
32
Synthesis and SAR evaluation of 1,2,4-triazoles as A(2A) receptor antagonists.

F. Hoffmann-La Roche
11
Synthesis and evaluation of adenosine derivatives as A

Institute of Medical Biology Pas
25
Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A

Sun Yat-Sen University
12
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as adenosine receptor antagonists. Influence of the N5 substituent on the affinity at the human A 3 and A 2B adenosine receptor subtypes: a molecular modeling investigation.

Università
32
Discovery of Potent and Selective Methylenephosphonic Acid CD73 Inhibitors.

Arcus Biosciences
70
3,4-Dihydropyrimidin-2(1

Universidade De Santiago De Compostela
16
Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A

University of Cologne
17
Direct Comparison of (N)-Methanocarba and Ribose-Containing 2-Arylalkynyladenosine Derivatives as A

National Institute of Diabetes and Digestive and Kidney Disease
21
Conjugable A

University of Trieste
15
Novel Irreversible Agonists Acting at the A

Monash University
18
Design, synthesis and biological evaluation of novel N-alkyl- and N-acyl-(7-substituted-2-phenylimidazo[1,2-a][1,3,5]triazin-4-yl)amines (ITAs) as novel A(1) adenosine receptor antagonists.

Università
39
Structure-affinity relationships of the affinity of 2-pyrazolyl adenosine analogues for the adenosine A2A receptor.

Cv Therapeutics
32
1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A(3) receptor ligands.

Nutrition Research Institute
4
Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A(3) adenosine receptor antagonist.

TBA
27
Discovery of first-in-class multi-target adenosine A

Universita Degli Studi Di Firenze
20
Pyrido[2,1-f]purine-2,4-dione derivatives as a novel class of highly potent human A(3) adenosine receptor antagonists.

Instituto De QuíMica MéDica (Csic)
10
2-Aminothiazoles: a new class of agonist allosteric enhancers of A(1) adenosine receptors.

University of Virginia
22
Adenosine A

Fudan University
71
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions.

National Institute of Diabetes & Digestive & Kidney Diseases
39
Biological Evaluation of 5'-(

National Institute of Diabetes and Digestive and Kidney Diseases
18
5'-Deoxy congeners of 9-(3-amido-3-deoxy-beta-D-xylofuranosyl)-N(6)-cyclopentyladenine: new adenosine A(1) receptor antagonists and inverse agonists.

Ghent University
36
1,8-disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists.

University of Bonn
36
Substituted 4-phenylthiazoles: Development of potent and selective A

University of Bonn
66
Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists.

Università
28
7-Substituted 5-amino-2-(2-furyl)pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as A2A adenosine receptor antagonists: a study on the importance of modifications at the side chain on the activity and solubility.

Università
15
Potent and selective A

Universit�
11
Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands.

Facoltà
17
New 8-amino-1,2,4-triazolo[4,3-a]pyrazin-3-one derivatives. Evaluation of different moieties on the 6-aryl ring to obtain potent and selective human A

Universita Degli Studi Di Firenze
12
Structural investigation on thiazolo[5,4-d]pyrimidines to obtain dual-acting blockers of CD73 and adenosine A

Universita Degli Studi Di Firenze
4
Fluorosulfonyl- and bis-(beta-chloroethyl)amino-phenylamino functionalized pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives: irreversible antagonists at the human A3 adenosine receptor and molecular modeling studies.

Università
13
Substituted 4-phenyl-2-(phenylcarboxamido)-1,3-thiazole derivatives as antagonists for the adenosine A(1) receptor.

Leiden/Amsterdam Center For Drug Research
26
C2-substituted quinazolinone derivatives exhibit A

North-West University
41
Nitrogen-Walk Approach to Explore Bioisosteric Replacements in a Series of Potent A

Uppsala University
4
High-pressure synthesis of enantiomerically pure C-6 substituted pyrazol.

AstraZeneca
15
2-Alkynyl-8-aryl-9-methyladenines as novel adenosine receptor antagonists: their synthesis and structure-activity relationships toward hepatic glucose production induced via agonism of the A(2B) receptor.

Eisai
6
Fluorosulfonyl-substituted xanthines as selective irreversible antagonists for the A(1)-adenosine receptor.

Deakin University
40
Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen.

Università
17
7-Deazaadenines bearing polar substituents: structure-activity relationships of new A(1) and A(3) adenosine receptor antagonists.

University of Leipzig
1
Design, radiosynthesis, and biodistribution of a new potent and selective ligand for in vivo imaging of the adenosine A(2A) receptor system using positron emission tomography.

University of Milano-Bicocca
42
Novel multi-target directed ligands based on annelated xanthine scaffold with aromatic substituents acting on adenosine receptor and monoamine oxidase B. Synthesis, in vitro and in silico studies.

Jagiellonian University Medical College
37
Synthesis and structure-activity relationships of a new set of 2-arylpyrazolo[3,4-c]quinoline derivatives as adenosine receptor antagonists.

Universita' Di Firenze
65
8-Substituted 1,3-dimethyltetrahydropyrazino[2,1-f]purinediones: Water-soluble adenosine receptor antagonists and monoamine oxidase B inhibitors.

University of Bonn
13
Focused screening to identify new adenosine kinase inhibitors.

University of Bonn
5
Controlling the Dissociation of Ligands from the Adenosine A2A Receptor through Modulation of Salt Bridge Strength.

Heptares Therapeutics
67
Novel non-xanthine antagonist of the A

Bayer Pharmaceuticals
20
Identification of new potent A

Nankai University
37
Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A(2B) adenosine receptors.

National Institute of Diabetes
39
1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists.

Universita' Di Firenze
40
Trifluorinated Pyrimidine-Based A

Uppsala University
56
Imidazopyridine-based selective and multifunctional ligands of biological targets associated with psychiatric and neurodegenerative diseases.

Palack£
3
Synthesis and preliminary biological evaluation of [3H]-MRE 3008-F20: the first high affinity radioligand antagonist for the human A3 adenosine receptors.

Università
9
Water-soluble phosphate prodrugs of 1-propargyl-8-styrylxanthine derivatives, A(2A)-selective adenosine receptor antagonists.

University of WüRzburg
32
Modifications on the Amino-3,5-dicyanopyridine Core To Obtain Multifaceted Adenosine Receptor Ligands with Antineuropathic Activity.

Universita Degli Studi Di Firenze
4
Design, Synthesis, and Characterization of Ogerin-Based Positive Allosteric Modulators for G Protein-Coupled Receptor 68 (GPR68).

Icahn School Of Medicine At Mount Sinai
27
Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A

Medical College of Wisconsin
13
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists.

Università
14
Selective A(3) adenosine receptor antagonists: water-soluble 3, 5-diacyl-1,2,4-trialkylpyridinium salts and their oxidative generation from dihydropyridine precursors.

National Institute of Diabetes
10
N-substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects.

Novo Nordisk
10
Selective A1-adenosine receptor antagonists identified using yeast Saccharomyces cerevisiae functional assays.

Cadus Pharmaceutical
8
Discovery of FR166124, a novel water-soluble pyrazolo-[1,5-a]pyridine adenosine A1 receptor antagonist.

Fujisawa Pharmaceutical
10
Chiral resolution and stereospecificity of 6-phenyl-4-phenylethynyl- 1,4-dihydropyridines as selective A(3) adenosine receptor antagonists.

National Institute of Diabetes
53
Accelerating the discovery of DGAT1 inhibitors through the application of parallel medicinal chemistry (PMC).

Merck
11
Development of Covalent Ligands for G Protein-Coupled Receptors: A Case for the Human Adenosine A

Leiden University
14
2-Aryladenine derivatives as a potent scaffold for A

Universidade Do Minho
31
Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2, 4-dialkylpyridine derivatives as selective A3 adenosine receptor antagonists.

National Institute of Diabetes
4
Docking Finds GPCR Ligands in Dark Chemical Matter.

Uppsala University
31
Structure-Based Optimization of Coumarin hA

University of Porto
37
Design and in Vivo Characterization of A

Medical College of Wisconsin
31
Functionalized 6-(Piperidin-1-yl)-8,9-Diphenyl Purines as Peripherally Restricted Inverse Agonists of the CB1 Receptor.

Rti International
6
The synthesis of new adenosine A3 selective ligands containing bioisosteric isoxazoles.

Novo Nordisk
36
Design, synthesis and biological evaluation of 2-hydrazinyladenosine derivatives as A

National Engineering Research Center For The Emergency Drug
44
A

Rheinische Friedrich-Wilhelms-Universitat Bonn
39
Derivatives of the triazoloquinazoline adenosine antagonist (CGS 15943) having high potency at the human A2B and A3 receptor subtypes.

National Institute of Diabetes
12
Thieno[2,3-d]pyrimidine as a promising scaffold in medicinal chemistry: Recent advances.

University of Science & Technology (Ust)
12
Design, synthesis, and biological evaluation of a second generation of pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as potent and selective A2A adenosine receptor antagonists.

Università
35
Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists.

Julius-Maximilians-UniversitäT WüRzburg
26
Novel human adenosine receptor antagonists based on the 7-amino-thiazolo[5,4-d]pyrimidine scaffold. Structural investigations at the 2-, 5- and 7-positions to enhance affinity and tune selectivity.

Universita Degli Studi Di Firenze
52
Structure-activity relationships of 4-(phenylethynyl)-6-phenyl-1,4-dihydropyridines as highly selective A3 adenosine receptor antagonists.

National Institute of Diabetes
23
Antioxidant-Conjugated 1,2,4-Triazolo[4,3-

Universita Degli Studi Di Firenze
23
The Medicinal Chemistry of Caffeine.

Goethe-University Frankfurt
13
Synthesis and structure-activity relationship of pyrazolo[3,4-d]pyrimidines: potent and selective adenosine A1 receptor antagonists.

Griffith University
18
Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype.

National Institute of Diabetes
35
Chiral pyrrolo[2,3-d]pyrimidine and pyrimido[4,5-b]indole derivatives: structure-activity relationships of potent, highly stereoselective A1-adenosine receptor antagonists.

Julius-Maximilians-UniversitäT WüRzburg
21
Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives: potent and selective A(2A) adenosine antagonists.

Università
15
Fragment-Based Discovery of Subtype-Selective Adenosine Receptor Ligands from Homology Models.

Stockholm University
23
Structure-Based Design, Synthesis by Click Chemistry and

National Institute of Diabetes and Digestive and Kidney Diseases
31
Interactions of flavonoids and other phytochemicals with adenosine receptors.

National Institute of Diabetes
14
Design and synthesis of fused tetrahydroisoquinoline-iminoimidazolines.

University of Lille
27
Tetrahydrobenzothiophenone derivatives as a novel class of adenosine receptor antagonists.

National Institute of Diabetes
3
Benzazaborinines as Novel Bioisosteric Replacements of Naphthalene: Propranolol as an Example.

Janssen Pharmaceutica
16
2-Aminopyrimidines as dual adenosine A1/A2A antagonists.

North-West University
34
Effect of trifluoromethyl and other substituents on activity of xanthines at adenosine receptors.

National Institutes of Health
9
Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A3 adenosine receptor antagonists and partial agonists.

Seoul National University
13
Novel 8-(p-substituted-phenyl/benzyl)xanthines with selectivity for the A2A adenosine receptor possess bronchospasmolytic activity.

Panjab University
30
Discovery of simplified N²-substituted pyrazolo[3,4-d]pyrimidine derivatives as novel adenosine receptor antagonists: efficient synthetic approaches, biological evaluations and molecular docking studies.

National University of Singapore
12
Replacement of amide with bioisosteres led to a new series of potent adenosine A2A receptor antagonists.

Soochow University
65
1,3-Dialkyl-substituted tetrahydropyrimido[1,2-f]purine-2,4-diones as multiple target drugs for the potential treatment of neurodegenerative diseases.

University of Bonn
25
Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.

University of Santiago De Compostela
17
8-(2-Furyl)adenine derivatives as A₂A adenosine receptor ligands.

University of Camerino
21
8-Azaxanthine derivatives as antagonists of adenosine receptors.

Università
10
Modulation of A2B adenosine receptor by 1-Benzyl-3-ketoindole derivatives.

University of Pisa
14
Design and synthesis of (4E)-4-(4-substitutedbenzylideneamino)-3-substituted-2,3-dihydro-2-thioxothiazole-5-carbonitrile as novel A2A receptor antagonists.

University of Delhi
35
Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors.

National Institute of Diabetes
8
Synthesis and biological evaluation of metabolites of 2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535), a potent antagonist of the A2A adenosine receptor for the treatment of Parkinson's disease.

University of Urbino
20
New insight into adenosine receptors selectivity derived from a novel series of [5-substituted-4-phenyl-1,3-thiazol-2-yl] benzamides and furamides.

B.V. Patel Pharmaceutical Education and Research Development
35
Dual targeting of adenosine A(2A) receptors and monoamine oxidase B by 4H-3,1-benzothiazin-4-ones.

University of Bonn
20
Novel adenosine A(2A) receptor ligands: a synthetic, functional and computational investigation of selected literature adenosine A(2A) receptor antagonists for extending into extracellular space.

Monash University (Parkville Campus)
48
Substituted thieno[2,3-d]pyrimidines as adenosine A2A receptor antagonists.

Janssen Research & Development
33
Tricyclic heteroaromatic systems. Synthesis and A1 and A2a adenosine binding activities of some 1-aryl-1,4-dihydro-3-methyl[1]benzopyrano[2,3-c] pyrazol-4-ones, 1-aryl-4,9-dihydro-3-methyl-1H-pyrazolo[3,4-b]quinolin-4- ones, and 1-aryl-1H-imidazo[4,5-b]quinoxalines.

Università
24
Synthesis, adenosine receptor binding and 3D-QSAR of 4-substituted 2-(2'-furyl)-1,2,4-triazolo[1,5-a]quinoxalines.

University of Santiago De Compostela
44
[1,2,4]Triazolo[1,5-c]pyrimidines as adenosine receptor antagonists: Modifications at the 8 position to reach selectivity towards A

University of Trieste
34
Analogues of caffeine and theophylline: effect of structural alterations on affinity at adenosine receptors.

TBA
24
Antagonists of the adenosine A

Umr-S1172 - Jparc - Centre De Recherche Jean-Pierre Aubert Neurosciences Et Cancer
22
The aminopyridine-3,5-dicarbonitrile core for the design of new non-nucleoside-like agonists of the human adenosine A

Universita Degli Studi Di Firenze
25
Discovery of Potent and Selective A

Advinus Therapeutics
21
Fluorescent-Labeled Selective Adenosine A

University of Bonn
17
Structure-activity relationship studies and pharmacological characterization of N

Universita Degli Studi Di Firenze
27
New potent and selective A

University of Camerino
38
Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions.

National Institutes of Health
4
An Affinity-Based Probe for the Human Adenosine A

AstraZeneca
18
Identification of novel thiazolo[5,4-d]pyrimidine derivatives as human A

Universita Degli Studi Di Firenze
12
Docking Screens for Dual Inhibitors of Disparate Drug Targets for Parkinson's Disease.

Uppsala University
19
Design and synthesis of 2,6-disubstituted-8-amino imidazo[1,2a]pyridines, a promising privileged structure.

Universities of Lille
49
Identification and biological evaluation of thiazole-based inverse agonists of RORγt.

Phenex Pharmaceuticals
10
Development of novel pyridazinone-based adenosine receptor ligands.

Universita Degli Studi Di Firenze
22
Imidazo[1,2-α]pyridines possess adenosine A

North-West University
23
Exploring the Role of N

University of Camerino
32
Indazole-6-phenylcyclopropylcarboxylic Acids as Selective GPR120 Agonists with in Vivo Efficacy.

AstraZeneca
20
Enantiospecific Recognition at the A

Uppsala University
17
A Structure-Activity Relationship Study of Bitopic N

Monash University
37
Identification of highly selective and potent orexin receptor 1 antagonists derived from a dual orexin receptor 1/2 antagonist based on the structural framework of pyrazoylethylbenzamide.

Taisho Pharmaceutical
10
Selected C8 two-chain linkers enhance the adenosine A

North-West University
21
Imidazo[1,2-a]pyrazin-8-amine core for the design of new adenosine receptor antagonists: Structural exploration to target the A

Universita Degli Studi Di Firenze
15
Effect of Nitrogen Atom Substitution in A

Uppsala University
8
Photoaffinity Labeling of the Human A

Kissei Pharmaceutical
16
Structure-Based Design, Synthesis, and In Vivo Antinociceptive Effects of Selective A

University of Camerino
15
Polypharmacology of N

Sahmyook University
30
Effects of alkyl substitutions of xanthine skeleton on bronchodilation.

Hokuriku University
894
KHK inhibitors

Gilead Sciences
20
Benzothiophene, thienopyridine and thienopyrimidine derivatives for the modulation of sting

Ctxt
43
Small-molecule focal adhesion kinase (FAK) inhibitors

Dana-Farber Cancer Institute
29
NUCLEOBASE-SUBSTITUTED PIPERIDINYL-PYRIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING DISEASES AND CONDITIONS

K36 Therapeutics
45
Class of DNA gyrase and/or topoisomerase IV inhibitors with activity against gram-positive and gram-negative bacteria

Univerza V Ljubljani
5
NOVEL AND HIGHLY SELECTIVE SARS-COV-2 MPRO INHIBITORS

The Wistar Institute of Anatomy and Biology
11
3-CYCLOAMINO-INDOLE COMPOUNDS AS SEROTONERGIC AGENTS USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Mindset Pharma
178
Thiazolopyridyl Amide Derivatives as DNA Polymerase Theta Inhibitors

Beigene
31
NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS

Gilgamesh Pharmaceuticals
45
SMALL-MOLECULE INHIBITORS FOR BETA-CATENIN/BCELL LYMPHOMA 9 PROTEIN-PROTEIN INTERACTION

H. Lee Moffitt Cancer Center and Research Institute
1
SALT FORM AND CRYSTAL FORM OF PYRAZOLE SUBSTITUTED IMIDAZO[1,2- A]QUINOXALINE DERIVATIVE

Ocumension Therapeutics (Suzhou) Co.
107
Substituted tetrahydrofurans as modulators of sodium channels

Vertex Pharmaceuticals
48
Spiropyrrolidine derived antiviral agents

Enanta Pharmaceuticals
108
RIPK1 INHIBITORS AND METHODS OF USE

Merck Sharp & Dohme
421
4-ALKOXYPYRROLO[2,1-F][1,2,4]TRIAZINES AND PREPARATION AND USES THEREOF

Biosplice Therapeutics
93
Substituted N-pyrimidin-4-yl-3-aminopyrrolo[3,4-C]pyrazoles as protein kinase C inhibitors

Pfizer
47
KCNT1 INHIBITORS AND METHODS OF USE

Praxis Precision Medicines
43
Compositions and methods for inhibiting kinases

Inhibikase Therapeutics
187
Cyanotriazole compounds

Otsuka Pharmaceutical
50
4-substitued cytisine analogues

University of Bristol
17
6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes

Sprint Bioscience
62
Substituted condensed thiophenes as modulators of sting

Ctxt Pty
50
Combination therapies using caspase-1 dependent anticancer agents and PGE2 antagonists

Tufts College
25
AROMATIC BRIDGED RING AMIDE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION

F. Hoffmann-La Roche
4
Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders

Mindset Pharma
209
2-amino-n-heteroaryl-nicotinamides as Nav1.8 inhibitors

Merck Sharp & Dohme
198
1-cyano-pyrrolidine derivatives as DUB inhibitors

Mission Therapeutics
85
3-(5-amino-pyrazin-2-yl)-benzenesulfonamide derivatives and related compounds as PI3K-gamma kinase inhibitors

Incyte
213
Tosylacetate based compounds and derivatives thereof as PHGDH inhibitors

Boehringer Ingelheim International
82
Tricyclic CRBN ligands and uses thereof

Kymera Therapeutics
172
Therapeutic compounds and uses thereof

Genentech
69
Compounds and methods for inhibiting JAK

Dizal (Jiangsu) Pharmaceutical
16
Phenylpyrazolylacetamide compounds and derivatives as CDK8/CDK19 inhibitors

Boehringer Ingelheim International
38
Substituted imidazoles as apoptosis signal regulating kinase 1 inhibitors

Jiangsu Hansoh Pharmaceutical Group
13
C7 substituted oxysterols and methods of use thereof

Sage Therapeutics
127
Aminopyrazine derivatives as PI3K-γ inhibitors

Incyte
135
Metalloenzyme inhibitor compounds

Phasebio Pharmaceuticals
44
Compounds and their use for reducing uric acid levels

Acquist
8
FXR (NR1H4) modulating compounds

Gilead Sciences
40
Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use

Amgen
16
1,2-dithiolane compounds useful in neuroprotection, autoimmune and cancer diseases and conditions

Sabila Biosciences
289
3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

GrÜNenthal
29
Cyclic di-nucleotide compounds as STING agonists

Merck Sharp & Dohme
5
Organic compounds

Intra-Cellular Therapies
15
HDAC inhibitors

Biomarin Pharmaceutical
108
Pyrazole, triazole and tetrazole orexin receptor antagonists

Merck Sharp & Dohme
61
Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure

Universitetet I Oslo
18
Methods of use of cyclopamine analogs

Infinity Pharmaceuticals
63
Heteroaromatic compounds as BTK inhibitors

Boehringer Ingelheim International
147
8-(piperazin-1-yl)-1,2,3,4-tetrahydro-isoquinoline derivatives

Idorsia Pharmaceuticals
2
Compounds as rearranged during transfection (RET) inhibitors

Glaxosmithkline
39
Inhibitors of human 12/15-lipoxygenase

The Children'S Hospital
30
Compounds for treatment of fibrosis diseases

Curegenix
70
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-B] pyridines and therapeutic uses thereof

Samumed
86
Substituted 5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-amine compounds as PDE2 inhibitors

Dart Neuroscience (Cayman)
5
Hydroxy-substituted amino and ammonium derivatives and their medical use

Gri Bio
5
Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases

Abbvie
137
TRPV1 antagonists including dihydroxy substituent and uses thereof

Purdue Pharma
28
Transformation of the Non-Selective Aminocyclohexanol-Based Hsp90 Inhibitor into a Grp94-Seletive Scaffold.

The University of Kansas
4
4-Fluoro-Thio-containing inhibitors of APP2, compositions thereof and method of use

TBA
394
Amidopyrazole inhibitors of interleukin receptor-associated kinases

Merck Sharp & Dohme
1
Rationally designed sulfamides as glutamate carboxypeptidase II inhibitors.

Washington State University At Pullman
22
Altered enthalpy-entropy compensation in picomolar transition state analogues of human purine nucleoside phosphorylase.

Albert Einstein College of Medicine
8
Neoflavonoids and Tetrahydroquinolones as Possible Cancer Chemopreventive Agents.

Central Institute of Medicinal and Aromatic Plants
8
Intersubunit bridge formation governs agonist efficacy at nicotinic acetylcholine α4β2 receptors: unique role of halogen bonding revealed.

University of Copenhagen
7
M2 and M3 muscarinic receptor activation of urinary bladder contractile signal transduction. I. Normal rat bladder.

Temple University
3
Inhibitory effect of the 4-aminotetrahydroquinoline derivatives, selective chemoattractant receptor-homologous molecule expressed on T helper 2 cell antagonists, on eosinophil migration induced by prostaglandin D2.

Kyowa Hakko Kogyo
1
Characterization of (2S,4R)-1-[5-chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist.

Sanofi-Synthelabo Recherche
3
Agonists and antagonists acting at P2X receptors: selectivity profiles and functional implications.

Biocentre Niederursel
8
Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles.

R. W. Johnson Pharmaceutical Research Institute
1
In vitro and in vivo profile of SB 206553, a potent 5-HT2C/5-HT2B receptor antagonist with anxiolytic-like properties.

Smithkline Beecham Pharmaceuticals
39
Pharmacologic characterization of the human 5-hydroxytryptamine2B receptor: evidence for species differences.

Eli Lilly
7
Molecular cloning and characterization of the human A3 adenosine receptor.

Merck Research Laboratories
16
Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications.

Maryland Psychiatric Research Center
162
CSF-1R INHIBITORS AND USES THEREOF

Myrobalan Therapeutics
10
Glycogen phosphorylase inhibitory effects of 2-oxo-1,2-dihydropyridin-3-yl amide derivatives.

Griffith University
14
Discovery of antibacterial biotin carboxylase inhibitors by virtual screening and fragment-based approaches.

Pfizer
30
Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta.

Takeda Pharmaceutical
5
Conformationally constrained farnesoid X receptor (FXR) agonists: Naphthoic acid-based analogs of GW 4064.

Gsk
4
Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.

Merck Research Laboratories
37
Carbonic anhydrase inhibitors. Cloning, characterization, and inhibition studies of a new beta-carbonic anhydrase from Mycobacterium tuberculosis.

Kochi Medical School
10
1-Sulfonylindazoles as potent and selective 5-HT6 ligands.

Wyeth Research
8
Discovery of 1-[9-(4-chlorophenyl)-8-(2-chlorophenyl)-9H-purin-6-yl]-4-ethylaminopiperidine-4-carboxylic acid amide hydrochloride (CP-945,598), a novel, potent, and selective cannabinoid type 1 receptor antagonist.

Pfizer
11
Isoxazolo[3,4-b]quinoline-3,4(1H,9H)-diones as unique, potent and selective inhibitors for Pim-1 and Pim-2 kinases: chemistry, biological activities, and molecular modeling.

Abbott Laboratories
21
Discovery of Boronic Acids as Novel and Potent Inhibitors of Fatty Acid Amide Hydrolase.

University of Oxford
19
Inhibitor Scaffolds for 2-Oxoglutarate-Dependent Histone Lysine Demethylases.

University of Oxford
30
Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines.

AstraZeneca
8
Probing the elusive catalytic activity of vertebrate class IIa histone deacetylases.

Irbm/Merck Research Laboratories
48
Interaction of papain-like cysteine proteases with dipeptide-derived nitriles.

Rheinische Friedrich-Wilhelms-Universitat Bonn
62
Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits.

Novartis Pharmaceuticals
18
Cholinesterase inhibitors: xanthostigmine derivatives blocking the acetylcholinesterase-induced beta-amyloid aggregation.

University of Bologna
32
5-aryl-pyrazolo[3,4-b]pyridines: potent inhibitors of glycogen synthase kinase-3 (GSK-3).

Glaxosmithkline
16
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.

Smithkline Beecham Pharmaceuticals
6
Structural-thermodynamic relationships of interactions in the N-terminal ATP-binding domain of Hsp90.

University College London